Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. Our flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning. It is currently being introduced globally through selected partners and the company's own brand platform. In parallel, we are advancing NPP-4, a next-generation cosmetic peptide innovation designed to enhance skin tone.
With scalable in-house production, established intellectual property, and a flexible commercial model, Coegin Pharma is positioned to bring differentiated, science-based products to the global cosmetics market.
Coegin Pharma's share is listed on the NGM Growth Market and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.
Built on research from leading academic institutions and supported by collaborations with universities and partners.
One patented peptide already launched globally, with NPP-4 advancing toward market.
Addressing underserved needs in hair density and skin toning within the expanding global longevity trend.
Driving efficient market entry through flexible collaborations to maximize reach and impact.